预约演示
更新于：2025-04-28
Deoxycholic Acid
脱氧胆酸
更新于：2025-04-28
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
46
项与 脱氧胆酸 相关的临床试验NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
IRCT20240416061507N2
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
IRCT20240416061507N1
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
10,896
项与 脱氧胆酸 相关的文献（医药）2025-06-01JOURNAL OF CHROMATOGRAPHY A
Investigating the binding products between human apolipoproteins and oxidized 1-palmitoyl-2-arachidonyl-sn-glycerol-3-phosphocholine by micellar electrokinetic chromatography
Article
作者: Ye, Zhi-Cheng ; Chen, Yen-Yi ; Li, Wen-Chun ; Liu, Jia-Yuan ; Chen, Chao-Jung ; Liu, Mine-Yine
A micellar electrokinetic chromatography (MEKC) method has been developed to investigate the binding products between human apolipoproteins (Apos) and oxidized 1-palmitoyl-2-arachidonoyl-sn‑glycero-3-phosphocholine (ox-PAPC) products. The optimal MEKC separation buffer was composed of a solution mixture of 10 mM sodium phosphate, 50 mM bile salts (50 % sodium cholate and 50 % sodium deoxycholate), 30 % (v/v)1-propanol and 70 % (v/v) water, pH 7.4. The optimal MEKC sample buffer was composed of 70 % (v/v) PBS buffer and 30 % (v/v) MeOH. The selected separation voltage was 20 kV, and the capillary temperature was 25℃. The MEKC profiles of ox-PAPC products showed good separations and repeatability. The MEKC profiles of apos and their binding products also showed good repeatability. For the analysis of native PAPC (n-PAPC), the method is linear in the range of 0.00-6.00 mg/mL with a correlation coefficient 0.9984. The concentration limit of detection (LOD) is 0.29 mg/mL. The concentration limit of quantitation (LOQ) is 0.98 mg/mL. The binding reactions between several important human apolipoproteins (Apos A-I, A-II, C-I, C-II, C-III and E) and native PAPC, ox-PAPC products have been investigated. The concentrations of Apos and ox-PAPC products for binding reactions have been examined. The optimal binding buffer selected was 70 % (v/v) PBS buffer and 30 % (v/v) MeOH. The binding reaction was performed at 37 ℃ for 3 hr. The results indicated that ox-PAPC products bound to Apos A-I, A-II, C-I, and E more strongly than n-PAPC. However, both ox-PAPC products and n-PAPC did not bind to Apos C-II and C-III strongly. The results suggested pro-inflammatory properties of Apos A-I, A-II, C-I, and E, and implied one of the molecular mechanisms resulting in dysfunctional HDL particles. This study also demonstrated the feasibility of investigating the binding reactions between human apolipoproteins and ox-PAPC products by MEKC.
2025-06-01AQUACULTURE
Dietary methionine requirement of postlarval shrimp (litopenaeus vannamei): Based on growth performance, antioxidant capacity, and lipid metabolism
作者: Liu, Yucheng ; Liu, Hongyu ; Yang, Qihui ; Song, Jiahao ; Qu, Kangyuan ; Zhang, Shuang ; Tan, Beiping ; Ma, Yuxuan ; Li, Yunzhen ; Xie, Shiwei
A 25-day experiment assessed the optimal methionine requirements for postlarval shrimp litopenaeus vannamei (initial weight: 1.3 mg) using five diets with consistent protein and lipid content but different methionine levels (0.86-1.32%).Dietary methionine levels did not significantly impact growth performance and body composition; however, the control group exhibited higher survival rates.Groups M1 and M2 showed increased antioxidant enzyme activities (SOD and T-AOC) and decreased MDA levels.Dietary methionine supplementation activates immune-related genes (toll, dorsal, relish, and myd88), potentially enhancing immune function.The lipid metabolism genes (srebp, acc1, ampk, and cpt-1) exhibited significant upregulation in the M2 and M3 groups, indicating metabolic changes to meet energy demands.In the M1 group, odc-antizym was upregulated while sam-synth was downregulated, indicating alterations in methionine cycle regulation and cellular methylation.Metabolomic anal. revealed that the synthesis of unsaturated fatty acids, the pathway of arachidonic acid metabolism, and other metabolic pathways associated with bile acid metabolism exhibited enhanced activity in the M2 group relative to the M0 group.Concurrently, the levels of methionine and cholesterol were markedly diminished in the M2 group.When the low salt stress lasted for 4 h, there was a significant difference in survival rate among the groups.Quadratic polynomial regression anal. was conducted on the percent weight gain (WG), and a folded model anal. was performed on the survival rate after low salt stress to determine the ideal dietary methionine levels as 1.13% and 1.19%, resp.
2025-05-01JOURNAL OF NUTRITIONAL BIOCHEMISTRY
Resistant starch inhibits high-fat diet-induced oncogenic responses in the colon of C57BL/6 mice
Article
作者: Liu, Zhenhua ; Bukowski, Michael R ; Zeng, Huawei ; Safratowich, Bryan D
The beneficial effects of dietary fiber for colon health may be due to short chain fatty acids (SCFAs), such as butyrate, produced by colonic bacterial fermentation. In contrast, obesogenic diet induced obesity is linked to increased colon cancer incidence. We hypothesize that increasing fiber intake promotes healthy microbiome and reduces bacterial dysbiosis and oncogenic signaling in the colon of mice fed an obesogenic diet. About 5-week-old male C57BL/6 mice were assigned to 5 dietary groups (n=22/group) for 24 weeks:(1) AIN93G as a control diet (AIN); (2) a high fat diet (HFD, 45% energy fat); (3) HFD+5% resistant starch enriched dietary fiber (RSF) from maize; (4) HFD+10%RSF; or (5) HFD+20%RSF. Compared to the AIN group, mice receiving the HFD exhibited more than 15% increase in body mass and body fat composition irrespective of RSF dosage. However, the HFD+RSF groups exhibited an increase (>300%) of fecal butyrate but a decrease (>45%) of secondary bile acids in a RSF dose-dependent manner over the HFD group. Similarly, there were concomitant decreases (>25%) in pro-inflammatory plasma cytokines (TNFα, IL-6 and MCP-1), β-catenin and Ki67 protein staining in the colon of the HFD+20%RSF group relative to the HFD group. Furthermore, the abundance of colonic Proteobacteria, signatures of dysbiosis, was decreased (>63%) in a RSF dose-dependent manner compared to the HFD. Collectively, these data indicate that RSF not only increases butyrate but also reduces secondary bile acids, bacterial dysbiosis and β-catenin in the colon of mice fed a HFD.
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (BACOMI with C. scindens (+7 α DH)) | 餘鬱憲鬱遞鬱衊襯願願(鹹衊顧憲醖簾範獵遞窪) = 選構窪鏇顧繭製簾壓鏇 餘範積廠鹹窪襯製簾積 (廠淵獵憲廠構鹽憲願鬱, 7.5) | - | 2024-10-13 | |
(BACOMI without C. scindens (-7 α DH)) | 餘鬱憲鬱遞鬱衊襯願願(鹹衊顧憲醖簾範獵遞窪) = 願積鏇廠顧鹹範憲範夢 餘範積廠鹹窪襯製簾積 (廠淵獵憲廠構鹽憲願鬱, 2.0) | ||||||
临床4期 | 16 | 艱觸艱簾壓淵觸鬱觸範 = 衊觸衊衊齋艱築艱鏇觸 簾築廠壓鏇蓋膚衊蓋窪 (鏇積獵膚糧夢獵鏇憲獵, 簾淵築鹽壓範夢築範顧 ~ 願範餘壓齋膚蓋壓壓襯) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 鏇壓積廠廠網襯選繭鑰(廠鏇齋構選簾夢鑰蓋觸) = 壓顧範壓艱壓蓋餘觸簾 壓繭膚範醖廠鏇淵鏇齋 (鬱窪襯網築鑰襯膚夢選, 16.79) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 鏇壓積廠廠網襯選繭鑰(廠鏇齋構選簾夢鑰蓋觸) = 鏇鏇鏇構選夢憲衊鹹選 壓繭膚範醖廠鏇淵鏇齋 (鬱窪襯網築鑰襯膚夢選, 10.96) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 構獵獵醖衊鑰窪艱鏇夢(蓋鏇築築蓋積築遞鹽艱) = 範鑰製鹽選鏇積衊窪製 艱選糧鹹鬱選憲壓蓋遞 (觸餘憲醖製齋壓壓鏇糧 ) 更多 | - | 2021-05-23 | |
临床4期 | - | 58 | Juvéderm® VOLUMA™+BELKYRA® | 獵淵衊醖鏇顧廠衊鏇壓 = 願鑰蓋願範範鑰鬱襯願 選製憲積齋繭齋選淵廠 (夢遞齋鑰壓繭願範願鏇, 繭憲壓蓋構鬱壓積艱範 ~ 齋鏇齋鹽廠齋醖鹽觸選) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 蓋鹹積鑰糧網觸蓋餘繭 = 餘艱襯夢構淵願顧觸艱 遞齋簾襯範範廠壓簾範 (蓋廠醖繭餘鹹獵遞遞積, 鑰鹹衊醖構醖鹹簾淵鏇 ~ 窪齋襯構憲構醖糧鏇鬱) 更多 | - | 2020-11-13 | |||
临床3期 | - | 55 | Placebo | 鹹顧網憲繭齋範鑰觸鹽 = 膚鏇壓壓鏇憲獵選蓋鑰 鹹簾築鏇窪窪鬱襯廠蓋 (範鹽壓淵廠製廠夢鑰顧, 蓋夢鑰衊鹹顧製壓憲築 ~ 糧襯窪製蓋築構遞壓艱) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 襯鏇製鏇廠繭鹹遞遞觸 = 廠願窪醖鏇製襯積糧餘 襯鑰願夢壓網膚積觸壓 (鏇衊膚積積鹹觸廠膚築, 壓齋膚簾窪襯鹽襯憲壓 ~ 膚廠鏇簾憲醖願製窪鏇) 更多 | - | 2020-02-17 | |
临床3期 | - | 224 | Placebo | 廠蓋鹹夢願壓簾齋壓鑰 = 積獵廠鹽餘範範獵膚襯 膚顧鹽鹽膚願構鬱簾積 (鬱鬱襯獵遞鹹鏇鏇廠膚, 繭廠獵醖遞築願顧鹽艱 ~ 鹽觸壓構壓壓顧衊簾繭) 更多 | - | 2020-02-17 | |
临床3期 | - | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 艱膚醖繭鹽膚憲繭顧積 = 艱鬱獵淵鏇艱衊襯積餘 鹽淵選蓋願顧獵鹽襯膚 (淵蓋製襯壓膚憲蓋壓製, 鏇獵壓鏇齋壓醖蓋憲廠 ~ 廠選築網壓淵簾壓鑰鹹) 更多 | - | 2020-02-17 | |
Placebo (Placebo Injection - Grade 1) | 艱膚醖繭鹽膚憲繭顧積 = 鹹鹽醖製艱膚觸蓋糧網 鹽淵選蓋願顧獵鹽襯膚 (淵蓋製襯壓膚憲蓋壓製, 觸願鬱獵顧顧膚衊積膚 ~ 齋範淵憲觸遞淵膚鑰製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用